Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C52H88N10O15.2C2H4O2 |
Molecular Weight | 1213.417 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CC(O)=O.[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@]3([H])[C@@H](O)CCN3C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O
InChI
InChIKey=OGUJBRYAAJYXQP-IJFZAWIJSA-N
InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1
Caspofungin is an echinocandin antifungal drug, which is approved and is sold under the brand worldwide name cancidas. Caspofungin inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Cancidas is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients. Also is indicated for the treatment of esophageal candidiasis in adult and pediatric patients and for the treatment of invasive aspergillosis in adult and pediatric patients, but has not been studied as initial therapy for invasive aspergillosis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20930076
Curator's Comment: The ability to penetrate the blood-CSF/blood-brain barrier is poor as a consequence of their high molecular mass
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16162025 |
|||
Target ID: CHEMBL2364674 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16162025 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CANCIDAS Approved UseCANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. Treatment of esophageal candidiasis [see Clinical Studies (14.3) Launch Date2001 |
|||
Curative | CANCIDAS Approved UseCANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. Treatment of esophageal candidiasis [see Clinical Studies (14.3) Launch Date2001 |
|||
Curative | CANCIDAS Approved UseCANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. Treatment of esophageal candidiasis [see Clinical Studies (14.3) Launch Date2001 |
|||
Curative | CANCIDAS Approved UseCANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. Treatment of esophageal candidiasis [see Clinical Studies (14.3) Launch Date2001 |
|||
Curative | CANCIDAS Approved UseCANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida. Treatment of esophageal candidiasis [see Clinical Studies (14.3) Launch Date2001 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.65 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day steady-state, intravenous dose: 50 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.51 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
107.2 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day steady-state, intravenous dose: 50 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
88.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day steady-state, intravenous dose: 50 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
15.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25139840 |
50 mg 1 times / day multiple, intravenous dose: 50 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
CASPOFUNGIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3% |
CASPOFUNGIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
113 mg 1 times / day multiple, intravenous (starting) Overdose Dose: 113 mg, 1 times / day Route: intravenous Route: multiple Dose: 113 mg, 1 times / day Sources: |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Population Size: 1 Sources: |
|
50 mg/m2 1 times / day multiple, intravenous (starting) Recommended Dose: 50 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / day Sources: |
unhealthy, 2-11 years n = 171 Health Status: unhealthy Age Group: 2-11 years Population Size: 171 Sources: |
Disc. AE: Hypotension, Rash... AEs leading to discontinuation/dose reduction: Hypotension (1 patient) Sources: Rash (1 patient) |
70 mg single, intravenous (starting) Dose: 70 mg Route: intravenous Route: single Dose: 70 mg Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Kounis syndrome... |
70 mg single, intravenous (starting) Dose: 70 mg Route: intravenous Route: single Dose: 70 mg Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Age Group: 86 years Sex: M Population Size: 1 Sources: |
Disc. AE: Toxic epidermal necrolysis... AEs leading to discontinuation/dose reduction: Toxic epidermal necrolysis (severe, 1 patient) Sources: |
250 mg single, intravenous Highest studied dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: |
healthy, adult n = 6 Health Status: healthy Age Group: adult Population Size: 6 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | 1 patient Disc. AE |
50 mg/m2 1 times / day multiple, intravenous (starting) Recommended Dose: 50 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / day Sources: |
unhealthy, 2-11 years n = 171 Health Status: unhealthy Age Group: 2-11 years Population Size: 171 Sources: |
Rash | 1 patient Disc. AE |
50 mg/m2 1 times / day multiple, intravenous (starting) Recommended Dose: 50 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 50 mg/m2, 1 times / day Sources: |
unhealthy, 2-11 years n = 171 Health Status: unhealthy Age Group: 2-11 years Population Size: 171 Sources: |
Kounis syndrome | grade 5, 1 patient | 70 mg single, intravenous (starting) Dose: 70 mg Route: intravenous Route: single Dose: 70 mg Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Age Group: 58 years Sex: M Population Size: 1 Sources: |
Toxic epidermal necrolysis | severe, 1 patient Disc. AE |
70 mg single, intravenous (starting) Dose: 70 mg Route: intravenous Route: single Dose: 70 mg Sources: |
unhealthy, 86 years n = 1 Health Status: unhealthy Age Group: 86 years Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.pmda.go.jp/drugs/2012/P201200014/170050000_22400AMX00036_I100_1.pdf#page=15 Page: (PMDA_I100) 15-16 |
likely | |||
Sources: https://www.pmda.go.jp/drugs/2012/P201200014/170050000_22400AMX00036_I100_1.pdf#page=23 Page: (PMDA_I100) 23 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2012/P201200014/170050000_22400AMX00036_I100_1.pdf#page=16 Page: (PMDA_I100) 16 |
no | |||
Sources: https://www.pmda.go.jp/drugs/2012/P201200014/170050000_22400AMX00036_I100_1.pdf#page=15 Page: (PMDA_I100) 15 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Caspofungin acetate: an antifungal agent. | 2001 Jul 1 |
|
Caspofungin acetate, bivalirudin. | 2001 Oct 1 |
|
Moisture assay of an antifungal by near-infrared diffuse reflectance spectroscopy. | 2002 Apr 1 |
|
Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. | 2002 Aug 1 |
|
Safety and tolerability of caspofungin acetate in the treatment of fungal infections. | 2002 Mar |
|
Successful treatment of subcutaneously disseminated aspergillosis with caspofungin acetate in an allogeneic peripheral blood stem cell transplantation patient. | 2003 Apr |
|
Effects of amphotericin B and caspofungin on histamine expression. | 2003 Aug |
|
Gateways to clinical trials. | 2003 Dec |
|
Comment: caspofungin acetate for treatment of invasive fungal infections. | 2003 Dec |
|
Gateways to clinical trials. | 2003 Jan-Feb |
|
Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent. | 2003 May |
|
Aspergillus nidulans RhoA is involved in polar growth, branching, and cell wall synthesis. | 2004 Jan |
|
Gateways to clinical trials. | 2004 Jul-Aug |
|
Gateways to clinical trials. | 2004 Jun |
|
Gateways to clinical trials. | 2004 Mar |
|
Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. | 2004 May |
|
Gateways to clinical trials. | 2004 Oct |
|
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. | 2004 Sep 30 |
|
Gateways to clinical trials. | 2005 Jan-Feb |
|
Gateways to clinical trials. | 2005 Jun |
|
Gateways to clinical trials. | 2005 Mar |
|
Fatal Blastoschizomyces capitatus sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece. | 2005 May |
|
Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection. | 2006 Aug 8 |
|
Gateways to clinical trials. | 2006 Jan-Feb |
|
FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. | 2006 Jul |
|
Comparison of antifungal treatments for murine fusariosis. | 2006 Nov |
|
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery. | 2008 Mar 1 |
|
Gateways to Clinical Trials. | 2008 Nov |
|
Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B. | 2008 Nov |
|
Gateways to clinical trials. | 2010 Jun |
|
Recent advances in the treatment of mucormycosis. | 2010 Nov |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
Administer CANCIDAS (caspofungin acetate) by slow intravenous (IV) infusion over approximately 1 hour. Do not administer CANCIDAS by IV bolus administration.
Recommended Dosage in Adult Patients [18 years of age and older] The dosage and duration of CANCIDAS treatment for each indication are as follows: Empirical Therapy for Presumed Fungal Infections in Febrile Neutropenic Patients Administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based on the patient’s clinical response. Continue empirical therapy until resolution of neutropenia. In general, treat patients found to have a fungal infection for a minimum of 14 days after the last positive culture and continue treatment for at least 7 days after both neutropenia and clinical symptoms are resolved. If the 50-mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg. Candidemia and Other Candida Infections: administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be dictated by the patient’s clinical and microbiological response. In general, continue antifungal therapy for at least 14 days after the last positive culture. Patients with neutropenia who remain persistently neutropenic may warrant a longer course of therapy pending resolution of the neutropenia.
Esophageal Candidiasis: the dose is 50 mg once daily for 7 to 14 days after symptom resolution. A 70-mg loading dose has not been studied for this indication. Because of the risk of relapse of oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy could be considered. Invasive Aspergillosis: administer a single 70-mg loading dose on Day 1, followed by 50 mg once daily thereafter. Duration of treatment should be based upon the severity of the patient’s underlying disease, recovery from immunosuppression, and clinical response.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17785281
It was evaluated the susceptibility of 27 clinical isolates of Pythium insidiosum to caspofungin in vitro. Three reading criteria for MICs were adopted: MIC0, MIC1 and MIC2 (100%, 90% and 50% growth inhibition, respectively). Of the isolates 51.8% had an MIC0 of 64 mg/L, 88.8% of isolates had an MIC1 between 8 and 64 mg/L and 62.9% of isolates had a minimum fungicidal concentration of 64 mg/L. The results showed that caspofungin had limited fungistatic activity against P. insidiosum.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
282363
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
m3159
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
VUW370O5QE
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
100000089286
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
C1724
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
DBSALT000020
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
59900
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
KK-07
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
SUB12476MIG
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
VUW370O5QE
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
DTXSID60904590
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
16119813
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL499808
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY | |||
|
179463-17-3
Created by
admin on Fri Dec 15 16:09:54 GMT 2023 , Edited by admin on Fri Dec 15 16:09:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD